

REPLIDYNE INC  
Form 8-K  
October 23, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported) October 23, 2006

**REPLIDYNE, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

*(State or other jurisdiction of  
incorporation or organization)*

**000-52082**

*(Commission File Number)*

**84-1568247**

*(I.R.S. Employer  
Identification No.)*

**1450 Infinite Drive,  
Louisville, Colorado**

*(Address of principal executive offices)*

**80026**

*(Zip Code)*

**720-996-5500**

*(Registrant's telephone number, including area code)*

**Not Applicable**

*(Former name, former address and former fiscal year, if changed since last report)*

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**INFORMATION TO BE INCLUDED IN THE REPORT**

**Section 7 Regulation FD**

**Item 7.01 Regulation FD Disclosure.**

On October 23, 2006, Replidyne, Inc. (the Company ) issued a press release announcing that the U.S. Food and Drug Administration ( FDA ) has issued a non-approval letter for the Company s new drug application for faropenem medoxomil that was submitted to the FDA in Decmeber 2005. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

In accordance with General Instruction B.2. of Form 8-K, the information presented under this Item 7.01 and attached as Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

**Section 9 Financial Statements and Exhibits**

**Item 9.01 Financial Statements and Exhibits.**

(c) *Exhibits.*

- 99.1 Press Release, dated October 23, 2006, Entitled U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem.
-

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**REPLIDYNE, INC.**

Dated: October 23, 2006

By: /s/ Mark L. Smith  
Mark L. Smith  
Chief Financial Officer  
Principal Accounting Officer

---

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press Release, dated October 23, 2006, Entitled U.S. Food and Drug Administration Issues Non-Approvable Letter for Faropenem.